Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group.

N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.

2.

A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.

Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK; Degarelix Study Group.

J Urol. 2008 Nov;180(5):1986-92. doi: 10.1016/j.juro.2008.07.033. Epub 2008 Sep 17.

PMID:
18801505
3.

Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.

Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z; 037 Study Group.

Urology. 2008 Sep;72(3):488-93. doi: 10.1016/j.urology.2008.05.019. Epub 2008 Jul 17.

PMID:
18639327

Supplemental Content

Loading ...
Support Center